Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Blog  ›  Melanotan I vs Melanotan II: A Simple Research Comparison

Melanotan I vs Melanotan II: A Simple Research Comparison

Jun 11, 2026 4 min Other
TL;DR
Melanotan I and Melanotan II are both synthetic cousins of a natural skin-darkening hormone, but they work differently and have been studied at different doses. Research flagged both as widely used without medical oversight. Always treat dosing data as educational reference, not personal guidance.

Same Family, Different Molecules

Your body makes a hormone called alpha-melanocyte-stimulating hormone, or α-MSH. It tells pigment cells to produce melanin — the stuff that makes skin darken. Scientists built two synthetic copies of this hormone for research purposes. They named them Melanotan I and Melanotan II.

Think of them as cousins, not twins. They share a family resemblance but have different shapes, different potencies, and different research profiles.[1]

What Is Melanotan I?

Melanotan I (MT-I) is a straight-chain peptide — imagine a short string of amino acids lined up in a row. It mimics α-MSH closely. Researchers have studied it mainly for its pigmentation effects. One licensed medical version, called afamelanotide, is approved in some countries for a rare light-sensitivity disease.[2]

On the risk side, research has flagged that MT-I can activate dysplastic nevi — that means moles that already look abnormal could change further.[2] That's a serious concern worth knowing about.

What Is Melanotan II?

Melanotan II (MT-II) is a cyclic peptide — the chain loops back on itself. That loop makes it more compact and, researchers found, far more potent than MT-I.[4] It hits multiple melanocortin receptors, not just the ones involved in pigmentation. That broader reach is why its research effects go beyond skin color.

A landmark pilot study from 1996 gave healthy male volunteers subcutaneous (under-the-skin) injections starting at 0.01 mg/kg. Doses were stepped up slowly. At 0.025–0.03 mg/kg, researchers observed tanning, but also nausea, fatigue, and spontaneous erections.[4] More recent animal research found MT-II reversed memory problems caused by a high-fat diet in zebrafish — an early-stage finding, but intriguing.[3]

On the safety side, case reports have linked MT-II use to serious kidney events, including renal infarction — a blockage of blood flow to the kidney.[5] A qualitative study of online forums also found widespread misinformation and risky practices among people self-administering it.[6]

Quick Comparison

  • Structure: MT-I is linear; MT-II is cyclic (looped).
  • Potency: MT-II is described as "superpotent" compared to MT-I.[4]
  • Receptor targets: MT-I is more selective; MT-II hits multiple receptors.
  • Main research focus: MT-I → pigmentation and light sensitivity; MT-II → pigmentation, sexual function, appetite, and cognition.[1]
  • Research dosing (MT-II): Phase I trials started at 0.01 mg/kg, with 0.025 mg/kg suggested for future studies.[4]
  • Reported concerns: MT-I linked to mole changes[2]; MT-II linked to nausea, kidney events, and misuse.[5][6]
  • Regulatory status: Neither is approved for general use; both have been obtained online without oversight.[1]

How Research Dosing Is Reported

In published studies, doses are usually written as milligrams per kilogram of body weight (mg/kg). That means a heavier person receives a larger absolute dose. The 1996 MT-II trial used this approach, starting low and increasing carefully over two weeks.[4]

If you want to understand how those numbers translate into real figures, our calculator can help you work through the math — purely for educational purposes.

It's worth repeating: research dosing protocols exist to test safety and effects in controlled settings. They are not personal recommendations.

How to Choose What to Read About

Here's a simple decision guide:

  • Interested in pigmentation research with a more selective compound? Start with the Melanotan I page.
  • Curious about the broader receptor research — cognition, appetite, or the pilot clinical data? Head to Melanotan II.
  • Want to understand how body-weight-based dosing works in those studies? Use the calculator to follow along with the numbers.

Both peptides have been studied for decades, and both have generated real safety signals in that research.[1][6] Reading the actual study data — rather than forum posts — is always the better starting point.

The Bottom Line

Melanotan I and Melanotan II share a common origin but diverge significantly in structure, potency, and research scope. MT-I is more targeted; MT-II casts a wider net and has a longer list of documented effects and risks. Understanding those differences helps you read the science more clearly — which is exactly what this site is here to support.

Sources

  1. Use of melanotan I and II in the general population. — BMJ (Clinical research ed.), 2009. PMID 19224885.
  2. [Undesirable pigmentation]. — Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2015. PMID 26315100.
  3. Melanotan-II reverses memory impairment induced by a short-term HF diet. — Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023. PMID 37478579.
  4. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. — Life sciences, 1996. PMID 8637402.
  5. Melanotan II: a possible cause of renal infarction: review of the literature and case report. — CEN case reports, 2020. PMID 31953620.
  6. Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. — Dermatology (Basel, Switzerland), 2021. PMID 34464955.
See the dosage chart — Melanotan II
A melanocortin agonist researched for pigmentation and libido.
Melanotan II

FAQ

What is the main structural difference between Melanotan I and Melanotan II?
Melanotan I is a linear peptide — its amino acids form a straight chain. Melanotan II is cyclic, meaning the chain loops back on itself. That loop makes MT-II more compact and significantly more potent at melanocortin receptors. Researchers describe MT-II as 'superpotent' compared to its linear cousin, which also means its effects and side effects show up at lower doses.[4]
What doses were used in Melanotan II clinical research?
A 1996 Phase I pilot trial started male volunteers at 0.01 mg/kg via subcutaneous injection, stepping up in 0.005 mg/kg increments. The researchers suggested 0.025 mg/kg as the recommended dose for future Phase I studies. At 0.03 mg/kg, one participant experienced notable fatigue. These are research figures, not personal dosing advice.[4]
Are Melanotan I and Melanotan II approved medications?
A licensed version of Melanotan I called afamelanotide is approved in some countries for the rare disease erythropoietic protoporphyria. However, neither MT-I nor MT-II as sold online is an approved medication. Research has found both are widely purchased through unregulated internet sources without medical supervision, raising significant safety concerns.[1][2]
What safety concerns have researchers flagged for Melanotan II?
Studies and case reports have linked Melanotan II to nausea, somnolence, and spontaneous erections even at low research doses. More seriously, at least one case report identified a renal infarction — a dangerous blockage of blood flow to the kidney — possibly attributed to MT-II use. Online forum research also found widespread misinformation and risky self-administration practices.[5][6]
For research and educational use only. Not medical advice.